{"id":"dmxb-a","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Dizziness"},{"rate":"5-10%","effect":"Somnolence"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"DMXB-A acts by binding to the CB1 receptor, which is involved in the regulation of various physiological processes. This binding leads to the activation of the receptor, resulting in a range of downstream effects. The exact mechanisms by which DMXB-A exerts its therapeutic effects are not fully understood.","oneSentence":"DMXB-A is a potent agonist of the CB1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:33:38.428Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Epilepsy"}]},"trialDetails":[{"nctId":"NCT02458313","phase":"PHASE1","title":"Nicotinic Agonist Effects on BMI and Neuronal Response","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2016-04-14","conditions":"Obesity","enrollment":61},{"nctId":"NCT00100165","phase":"PHASE2","title":"Phase 2 Trial of a Nicotinic Agonist in Schizophrenia","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2005-01","conditions":"Schizophrenia","enrollment":29},{"nctId":"NCT01400477","phase":"PHASE2","title":"Nicotinic Receptors and Schizophrenia","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2011-07","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":97},{"nctId":"NCT02432066","phase":"PHASE2","title":"Effects of GTS-21 on Smoking Behavior and Neurocognitive Functions","status":"WITHDRAWN","sponsor":"University of Florida","startDate":"2018-09-29","conditions":"Tobacco Use Disorder","enrollment":""},{"nctId":"NCT02538081","phase":"PHASE1, PHASE2","title":"Nicotinic Receptors and Schizophrenia","status":"WITHDRAWN","sponsor":"VA Office of Research and Development","startDate":"2015-08","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT02111551","phase":"PHASE1","title":"Phase I Nicotinic Agonist Treatment Trial for Autism","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2015-06","conditions":"Autism","enrollment":2},{"nctId":"NCT00952393","phase":"PHASE1","title":"Nicotinic Receptors and Schizophrenia","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2010-01","conditions":"Schizophrenia","enrollment":10},{"nctId":"NCT00255918","phase":"PHASE1","title":"Investigation of the Drug Dimethoxbenzylidene Anabaseine in Treating Schizophrenia Patients","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2004-03","conditions":"Schizophrenia, Psychotic Disorders","enrollment":12},{"nctId":"NCT00783068","phase":"NA","title":"Anti-inflammatory Effects of GTS-21 After LPS","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2008-08","conditions":"Endotoxemia, Sepsis, Vagal Activity","enrollment":12},{"nctId":"NCT00419445","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of GTS21 in Adults With Attention-deficit Hyperactivity Disorder","status":"COMPLETED","sponsor":"CoMentis","startDate":"2007-02","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":37},{"nctId":"NCT00414622","phase":"PHASE2","title":"GTS21-201 for Alzheimer Disease:GTS-21 Administered Daily for 28 Days to Participants With Probable Alzheimer's Disease","status":"COMPLETED","sponsor":"CoMentis","startDate":"2006-11","conditions":"Alzheimer Disease","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["3-(2,4-dimethoxybenzylidene anabaseine"],"phase":"phase_2","status":"active","brandName":"DMXB-A","genericName":"DMXB-A","companyName":"CoMentis","companyId":"comentis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DMXB-A is a potent agonist of the CB1 receptor. Used for Epilepsy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}